Gianni, A., 2025
No toxic or adverse effects of intake of high riboflavin doses by humans have been reported so far ( Reference Said, Ross, Shils, Shike, Ross, Caballero and Cousins 14 , Reference Gallagher, Mahan, Escott-Stump, Raymond and Krause 16 )
When counseling patients concerned about access or cost following Medicare coverage changes, clinicians can use real-world data like this to reinforce that the therapeutic value of GLP-1s is well-documented, and that exploring alternative coverage pathways or manufacturer assistance programs is worth pursuing before discontinuing therapy
Hypoglycemia Despite having a pronounced anti-hyperglycemic effect, GLP-1 RAs are not typically associated with hypoglycemia when used as monotherapy
The retatrutide dosing protocol follows a similar escalation pattern to tirzepatide, starting low and increasing over several months
Results are still maturing